Renin-Angiotensin-Aldosterone System Modulates Blood Pressure Response During Vascular Endothelial Growth Factor Receptor Inhibition
Open Access
- 1 September 2019
- journal article
- research article
- Published by Elsevier in JACC: Cardiooncology
- Vol. 1 (1) , 14-23
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trialThe Lancet Oncology, 2019
- Genetic variants in the renin–angiotensin system predict response to bevacizumab in cancer patientsEuropean Journal of Clinical Investigation, 2015
- Vascular and Metabolic Implications of Novel Targeted Cancer TherapiesJACC, 2015
- Hypertension During Vascular Endothelial Growth Factor Inhibition: Focus on Nitric Oxide, Endothelin-1, and Oxidative StressAntioxidants & Redox Signaling, 2014
- Cardiovascular and Systemic MicrovascularEffects of Anti-Vascular Endothelial Growth Factor Therapy for CancerJACC, 2012
- Cardiac side effects of molecular targeted therapies: Towards a better dialogue between oncologists and cardiologistsCritical Reviews in Oncology/Hematology, 2011
- Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway InhibitorsJNCI: Journal of the National Cancer Institute, 2010
- VEGF Inhibition and Renal Thrombotic MicroangiopathyNew England Journal of Medicine, 2008
- Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditionsProceedings of the National Academy of Sciences, 2007
- Heterozygous embryonic lethality induced by targeted inactivation of the VEGF geneNature, 1996